Nov 22, 2019 · Levofloxacin is a fluoroquinolone antibiotic commonly used to treat a wide range of bacterial infections
Key Points
Implementation of the revisions is a challenge for all laboratories, as not all systems have FDA Levofloxacin is a bactericidal antibiotic of the fluoroquinolone drug class that directly inhibits bacterial DNA synthesis
Drug class: Quinolones
Levofloxacin is an antibiotic that may be used to treat certain bacterial
Using the updated 2019 CLSI breakpoints for FQs, the present study showed that the susceptibility of Enterobacterales to levofloxacin declined by 15
The review aims to provide a summary of low quality levofloxacin issues and the risk factors as well as suggesting the aspects of product quality that need to be
The pathogens responsible for bacteremia and those resistant to levofloxacin are listed in Table 2
Levofloxacin has been
Fluor eakpoin Enterobacteriaceae Pseudomonas aeruginosa Ciprofloxacin and levofloxacin are members of the fluoroquinolone group of antimicrobial agents
aeruginosa taken from pus and urine isolates in Surabaya from August 2005 to February 2006 showed that 42
pneumoniae
8) 03/2019 INDICATIONS AND USAGE Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥ 18 years of age) with infections caused by designated, susceptible bacteria (1, 12
3) Skin and skin structure infections: complicated (1
Levofloxacin tablet is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused 5/2019 Warnings and Precautions -Central Nervous System Effects (5
MHRA/CHM advice: Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long Common interactions include headache among females, and atrioventricular block complete among males
Prophylactic treatment with levofloxacin is an effective and well-tolerated way of preventing febrile episodes and other relevant infection-related outcomes in patients with cancer July 2023 Update
The product quality of antibacterial medicine will compromise patients' recovery and increase the chance of antibacterial resistance
S
Adjunctive therapy should be
Patients treated with levofloxacin for bacteremia caused by members of the Enterobacterales with high MICs (1 or 2 μg/ml; levofloxacin susceptible by pre-2019 CLSI breakpoints) were compared with those with low-MIC bacteremia (≤0
16
1
Methods: PubMed, Embase and Cochrane database were searched up to September 2018
1, and 55
Abstract